frontMIND
The first frontline regimen to beat R-CHOP in high-risk large B-cell lymphoma since rituximab, by adding a CD19 antibody and lenalidomide.
Median follow-up 35.2 months: 2-year PFS 71.1% vs 62.9%, HR 0.75 (Lancet 2026). OS immature (HR 0.85). Added haematologic toxicity. sBLA planned H1 2026.
Setting
Untreated high-risk DLBCL (IPI 3-5): tafasitamab + lenalidomide + R-CHOP vs placebo + R-CHOP
Phase
Phase 3
Sponsor
Incyte / MorphoSys
Registry
Headline result
PFS HR 0.75; 2-year PFS 71.1% vs 62.9%.
Reported
2025
Enrolled
899
In plain words
What these results mean for people, not percentages
Progression-free survival at 2 yearsprimarysurrogate endpoint
- 71.1 vs 62.9 out of 100 alive without the cancer growing at 2 years with Tafa-Len-R-CHOP compared with R-CHOP; 8.2 more per 100.
- Roughly one extra person helped for every 12 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 25 percent lower chance of the event at any given time (hazard ratio 0.75).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Untreated high-risk DLBCL (IPI 3-5): tafasitamab + lenalidomide + R-CHOP vs placebo + R-CHOP. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.